Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study

2.1 Primary Objectives • To determine whether implementing routine ePRO symptom monitoring during NAT in patients with PDAC improves patient health-related quality of life (HRQoL) and experience with care compared with the pre-implementation period.

o To capture participant HRQoL and experience, the primary outcomes will be measured using the PROMIS-16 and CAHPS Cancer Care Survey , respectively.

Eligibility Criteria

• Age ≥18 years
• Participants must have histologically confirmed PDAC that is respectable, borderline respectable, or locally advanced with potential for curative intent resection as defined by MD Anderson Cancer Center (Appendix V)
• Participants must be eligible to receive systemic neoadjuvant therapy (chemotherapy +/- radiation therapy) with intent for curative resection
• Participants who will receive neoadjuvant therapy at an MD Anderson facility including Texas Medical Center and Houston area locations
• Participants must be able to understand English or Spanish
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• Definitively unresectable or metastatic disease at enrollment
• Participants who received pre-referral chemotherapy, chemoradiotherapy, or previously attempted resection
• Participants who had prior curative intent surgery for pancreatic cancer before entering the study
• Participant with cognitive deficits that would preclude understanding of consent form and/or questionnaires
• Participants with psychiatric illness/social situations that would limit compliance with study requirements
• Participants who do not understand English or Spanish
• Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia
• Participants with uncontrolled underlying medical conditions
• Participants receiving chemotherapy outside of the MD Anderson system